These data suggest inhibition of Bcl-2 family members, most notably Bcl-xL, may enhance anti-JAK2 therapies for MPN, potentially leading to improved initial responses as well as decreased development of JAK2 inhibitor resistance. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.